|
1
|
Smyth MJ, Thia KYT, Cretney E, Kelly JM,
Snook MB, Forbes CA and Scalzo AA: Perforin is a major contributor
to NK cell control of tumor metastasis. J Immunol. 162:6658–6662.
1999.PubMed/NCBI
|
|
2
|
Smyth MJ, Swann J, Cretney E, Zerafa N,
Yokoyama WM and Hayakawa Y: NKG2D function protects the host from
tumor initiation. J Exp Med. 202:583–588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robertson MJ, Soiffer RJ, Wolf SF, Manley
TJ, Donahue C, Young D, Herrmann SH and Ritz J: Response of human
natural killer (NK) cells to NK cell stimulatory factor (NKSF):
Cytolytic activity and proliferation of NK cells are differentially
regulated by NKSF. J Exp Med. 175:779–788. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodolfo M and Colombo MP: Interleukin-12
as an adjuvant for cancer immunotherapy. Methods. 19:114–120. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colombo MP and Trinchieri G:
Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine
Growth Factor Rev. 13:155–168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Atkins MB, Robertson MJ, Gordon M, Lotze
MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone
PD, et al: Phase I evaluation of intravenous recombinant human
inter-leukin 12 in patients with advanced malignancies. Clin Cancer
Res. 3:409–417. 1997.PubMed/NCBI
|
|
7
|
Car BD, Eng VM, Lipman JM and Anderson TD:
The toxicology of interleukin-12: A review. Toxicol Pathol.
27:58–63. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ji J, Li J, Holmes LM, Burgin KE, Yu X,
Wagner TE and Wei Y: Glycoinositol phospholipid-anchored
interleukin 2 but secreted interleukin 2 inhibits melanoma tumor
growth in mice. Mol Cancer Ther. 1:1019–1024. 2002.PubMed/NCBI
|
|
9
|
Ji J, Li J, Holmes LM, Burgin KE, Yu X,
Wagner TE and Wei Y: Synergistic anti-tumor effect of
glycosylphosphatidylinositol-anchored IL-2 and IL-12. J Gene Med.
6:777–785. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peter ME and Krammer PH: The
CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26–35. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Houston A and O'Connell J: The Fas
signalling pathway and its role in the pathogenesis of cancer. Curr
Opin Pharmacol. 4:321–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kotturi HSR, Li J, Branham-O'Connor M,
Stickel SL, Yu X, Wagner TE and Wei Y: Tumor cells expressing a
fusion protein of MULT1 and Fas are rejected in vivo by apoptosis
and NK cell activation. Gene Ther. 15:1302–1310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kotturi HSR, Li J, Branham-O'Connor M, Yu
X, Wagner TE and Wei Y: In vitro and in vivo delivery of novel
anticancer fusion protein MULT1E/FasTI via adenoviral vectors.
Cancer Gene Ther. 17:164–170. 2010. View Article : Google Scholar
|
|
14
|
Law TM, Motzer RJ, Mazumdar M, Sell KW,
Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ and Bajorin
DF: Phase III randomized trial of interleukin-2 with or without
lymphokine-activated killer cells in the treatment of patients with
advanced renal cell carcinoma. Cancer. 76:824–832. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meropol NJ, Barresi GM, Fehniger TA, Hitt
J, Franklin M and Caligiuri MA: Evaluation of natural killer cell
expansion and activation in vivo with daily subcutaneous low-dose
interleukin-2 plus periodic intermediate-dose pulsing. Cancer
Immunol Immunother. 46:318–326. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elsässer-Beile U, Gierschner D, Welchner T
and Wetterauer U: Different expression of Fas and Fas ligand in
tumor infiltrating and peripheral lymphocytes of patients with
renal cell carcinomas. Anticancer Res. 23(1A): 433–437.
2003.PubMed/NCBI
|
|
17
|
Bryceson YT, March ME, Ljunggren HG and
Long EO: Activation, coactivation, and costimulation of resting
human natural killer cells. Immunol Rev. 214:73–91. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tietje A, Li J, Yu X and Wei Y:
MULT1E/mIL-12: A novel bi-functional protein for NK cell
activation. Cancer Res. 21:468–475. 2014.
|
